Skip to main content
TipRanks
Go Ultimate75% OFF

Globus Medical (GMED) AI Stock Analysis

1,028 Followers
GMED

Globus Medical

(NYSE:GMED)

Select Model
Rating:72Outperform
Price Target:$79.00â–²(12.06% Upside)
Action:reiterated
Date:11/07/26

GMED’s score is primarily supported by strong financial quality—minimal leverage and robust, improving cash flow—alongside healthy profitability. The main offsets are weak technicals (trading below major moving averages with low RSI) and a mixed earnings update, where revenue guidance was cut and near-term top-line pressure persists despite maintained EPS and margin improvement.

Positive Factors
Conservative Balance SheetVery low leverage gives Globus Medical substantial financial resilience and flexibility. The company can fund product development, technology investments and potential strategic actions without relying heavily on debt, while stronger equity supports stability through operating volatility.
Negative Factors
Revenue Growth DecelerationThe reduced outlook signals that near-term growth is below prior expectations, limiting confidence in the pace of expansion over the next several quarters. Delayed Spine launches and weaker Nevro performance also make the consolidated revenue trajectory less predictable.

Globus Medical Key Performance Indicators (KPIs)

Revenue By SegmentAnalyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.

$0.00$200.00M$400.00M$600.00M$800.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Muscoloskeletal Solutions became the engine for growth after a clear inflection in late‑2023 and has sustained dramatically higher quarterly revenue into 2025, concentrating sales exposure in the core business and creating material operating‑leverage upside if volumes hold. Enabling Technologies is growing but remains volatile and much smaller—Q4 2025 spike hints at product or commercial cadence rather than steady revenue. Neuromonitoring is immaterial except a one‑quarter blip, underscoring limited diversification.

Data provided by:The Fly

Globus Medical (GMED) vs. SPDR S&P 500 ETF (SPY)

-15%-10%-5%0%5%10%15%20%GMED-14.32%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$9.34B
Dividend Yield
―
Average Volume (3M)
1.61M
Price to Earnings (P/E)
17.0
Beta (1Y)
0.72
Revenue Growth
13.35%
EPS Growth
32.22%
Country
US
Employees
6,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Globus Medical Business Overview & Revenue Model

Company Description

Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extens...

How the Company Makes Money

Globus Medical generates revenue primarily by selling medical devices used in surgical procedures, with its core business historically centered on spine implants and the instruments and ancillary products required to implant them. Key revenue streams...

Globus Medical Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-13.43%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call was broadly constructive, supported by record free cash flow, expanding margins, strong Trauma and Enabling Technologies growth, continued product launches and maintained EPS guidance. However, near-term performance is being constrained by the 25.7% Nevro revenue decline, delayed Spine launches, weaker competitive recruiting, international softness and a reduction in 2026 revenue guidance. Management remained confident in the longer-term trajectory, particularly for 2027.

Positive Updates

Record Free Cash Flow and EPS Growth
Third-quarter revenue was $763.7 million, while non-GAAP diluted EPS was $1.23, growing 4.4% over the prior-year quarter. Free cash flow reached a record $225 million, growing 5%, and operating cash flow was $265 million, growing 6%, despite a 13% increase in capital expenditures.

Negative Updates

Consolidated Revenue Decline
Third-quarter revenue declined 0.7% on an as-reported basis and 0.5% on a constant-currency basis. Kyle Kline described consolidated sales as down 1% year over year, primarily driven by the 26% decline in Nevro revenue.

Company Guidance

For full year 2026, Globus Medical adjusted revenue guidance downward to $3.09 billion, compared to previous guidance of $3.18 billion to $3.22 billion, implying growth over 2025 of 5.1%; non-GAAP fully diluted earnings per share guidance remains in the range of $4.95 to $5.05, implying growth over 2025 ranging from 24.4% to 26.9%. The company reiterated adjusted gross profit margin in the range of 69% to 70% in 2026, representing a 90 to 190 basis point improvement over 2025, and expects R&D expense to be in the range of 4.5% to 5% of net sales for this year. Q4 guidance implies a mid-single-digit decline, while the company is not guiding on '27, though it said mid- to high single digits is where it would like to be for revenue growth, with earnings outperforming top line growth; it is also not guiding to free cash flow.

Globus Medical Financial Statement Overview

Summary

Financials are a net positive, led by a very strong balance sheet (very low leverage; debt-to-equity ~0.02) and robust, improving cash generation (TTM operating cash flow ~$926M; free cash flow ~$757M; free cash flow growth ~+79%). Profitability is healthy (TTM gross ~53%, EBIT ~16.6%, net ~17.8%), but the main risk is the recent TTM revenue decline (~-16.9%) and margin compression versus earlier years, which lowers growth confidence.

Income Statement

71Positive

Balance Sheet

88Very Positive

Cash Flow

86Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.14B2.94B2.52B1.57B1.02B958.10M
Gross Profit2.20B1.98B1.48B1.02B759.12M718.88M
EBITDA984.28M886.74M473.73M346.58M304.50M264.73M
Net Income557.67M537.90M102.98M122.87M190.17M149.19M
Balance Sheet
Total Assets5.53B5.30B5.25B5.09B2.08B1.96B
Cash, Cash Equivalents and Short-Term Investments517.43M557.24M890.06M517.79M446.06M443.45M
Total Debt107.55M118.66M537.19M520.40M6.01M0
Total Liabilities731.94M729.51M1.07B1.09B229.75M215.88M
Stockholders Equity4.80B4.57B4.18B4.00B1.85B1.74B
Cash Flow
Free Cash Flow756.55M588.77M405.21M165.22M104.42M219.38M
Operating Cash Flow925.92M753.45M520.64M243.50M178.47M276.27M
Investing Cash Flow-579.07M-355.01M-176.05M302.97M-110.36M-375.94M
Financing Cash Flow-233.84M-679.16M-27.70M-231.82M-109.96M54.15M

Globus Medical Technical Analysis

Technical Analysis SentimentNegative
Last Price70.50

Price Trends

50DMA76.40Negative
100DMA78.69Negative
200DMA82.60Negative

Market Momentum

MACD-1.40Positive
RSI39.58Neutral
STOCH7.54Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GMED, the sentiment is Negative. The current price of 70.50 is below the 20-day moving average (MA) of 78.31, below the 50-day MA of 76.40, and below the 200-day MA of 82.60, indicating a bearish trend. The MACD of -1.40 indicates Positive momentum. The RSI at 39.58 is Neutral, neither overbought nor oversold. The STOCH value of 7.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GMED.

Globus Medical Risk Analysis

Globus Medical disclosed 56 risk factors in its most recent earnings report. Globus Medical reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Globus Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GMED against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SYKSYK75Outperform$118.29B32.7415.61%1.13%7.87%22.82%
GMEDGMED72Outperform$9.34B17.0311.82%―13.35%32.22%
SIBNSIBN70Outperform$1.06B-75.31-7.57%―13.99%39.54%
ZBHZBH69Neutral$19.19B25.656.05%0.95%6.98%-2.22%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ATECATEC50Neutral$1.05B-12.11-547.17%―15.34%46.31%
OFIXOFIX44Neutral$277.17M-6.14-10.32%―2.12%63.59%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%GMEDATECOFIXSYKZBHSIBNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GMED and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GMEDGlobus Medical70.50-13.32-15.89%
ATECAlphatec6.78-12.84-65.44%
OFIXOrthofix Medical Inc.6.80-7.66-52.97%
SYKStryker Corp310.72-49.52-13.75%
ZBHZimmer Biomet Holdings101.4112.9114.58%
SIBNSi-Bone23.414.8125.86%

Globus Medical Corporate Events

Stock BuybackFinancial Disclosures

Globus Medical Reports Third-Quarter 2026 Earnings Growth

Positive
Nov 5, 2026

On November 5, 2026, Globus Medical reported third-quarter 2026 worldwide net sales of $763.7 million, down 0.7% year over year, while base-business sales excluding Nevro rose 3.0%. GAAP net income rose 18.7% to $141.2 million, diluted EPS increased...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026